Deploy an AI Agent for Document Processing in Biotechnology

Defensible delivery in a regulated environment

Biotechnology regulatory expectations on AI have hardened over the last twenty-four months. Supervisors who would once accept "we use AI in this workflow" as a sufficient disclosure now ask for the model card, the validation evidence, the override path, and the customer-disclosure language. Vendors who built for the looser bar are scrambling. We built for the harder bar from the start, because the engagement model we sell biotechnology teams is one we can defend in front of any reasonable supervisor.

For document processing, that defense rests on five artefacts the Build phase produces. The model card documents the deployed system: what it does, what it does not do, the training data lineage, the evaluation methodology, the known failure modes. The validation evidence is the labelled test set with its full provenance, the periodic eval reports, and the calibration curves. The override path is documented in the operator playbook and instrumented in the reviewer UI. The customer-disclosure language is drafted with your legal team during Build and tested with sample interactions before launch. The control map ties each control to a named owner and a measurable SLA.

The artefacts live in version control alongside the code, not in a shared drive. They are reviewed quarterly during Run and updated when the system changes. When a supervisor asks for them, the export is a single command. This is not theatre — it is the operating posture that lets your team say "yes, we use AI in this workflow, and here is the evidence we run it responsibly", with the evidence available in the time it takes to brew coffee.

Biotechnology sits inside a regulatory perimeter that an AI-native workflow has to inhabit, not bolt onto afterwards. For document processing, the perimeter includes: data residency rules for the source corpus, model-output traceability for any decision affecting a customer, replayability for the regulator's audit window, and named human accountability for every category of decision. We capture each of those requirements during Discovery, before any code is written, and the Build statement of work names which control implements which requirement. The output is an architecture where compliance is not a phase — it is a layer that lives in the same dashboard as the operating metrics.

The specific controls we ship for biotechnology engagements track the published expectations of the relevant supervisory bodies. The model registry records every prompt and model version that touched a decision, with an immutable hash. The retrieval index documents source provenance, freshness, and approval status per document. The reviewer queue captures the human owner, the timestamp, and the rationale for every escalation. The attestation pack — exportable on demand — bundles the above for any 30/60/90-day window the regulator chooses. This is the same shape that internal audit teams in biotechnology have been refining for a decade; we replicate it inside the AI-native operating layer instead of duplicating it in a separate evidence binder.

Where we depart from a traditional risk-and-controls program is in cadence. The classic posture treats compliance as an annual or quarterly attestation; the AI-native posture treats it as a weekly heartbeat. Every Monday during Run we sample low-confidence decisions, calibrate thresholds, and produce a drift report. Every quarter we run a red-team exercise on the most consequential flows. The compliance officer joining one of those Monday reviews sees the same dashboard the operators see, with attestation-ready evidence one click away. That continuity is what auditors recognize as a controlled environment, and it is what lets biotechnology leadership defend the workflow when the next supervisory examination arrives.

Third-party risk management for AI components in biotechnology is a growing concern that most workflows handle poorly. document processing engagements typically depend on a model provider, a retrieval store, a vector database, sometimes a fine-tuning service. Each is a vendor in your risk register. We map them all during Build, document substitution paths for each, and demonstrate substitutability in the eval harness — so when one vendor changes pricing, terms, or availability, the workflow can move without a re-architecture.

From kickoff to thin-slice production

The first 30 days of Build on document processing for biotechnology follow a deliberate rhythm we have refined over multiple engagements. The pattern is not "deliver the whole workflow then test"; it is "deliver vertical slices, each production-ready, with the next slice scoped from the prior slice's evidence".

Slice 1 (week 1-2): the retrieval and intake layer running against a curated subset of your data, with the labelled test set captured and the eval harness wired up. Outcome: we can prove the system finds the right context for a representative range of biotechnology cases. Slice 2 (week 3-4): the action layer drafting outputs that a reviewer approves before they hit production. Outcome: we can prove the system generates defensible drafts at a measurable accuracy rate. Slice 3 (week 5-6): low-confidence routing live, high-confidence automation gated by a calibration threshold. Outcome: we can prove the throughput-quality tradeoff is favourable on real production traffic. Subsequent slices widen the automation envelope, expand the integration surface, and add the reporting layer.

The vertical-slice cadence is what lets your team see compounding evidence rather than waiting for a big-bang reveal. It also lets us catch architectural issues early — week 2 evaluation results that surprise us are far cheaper to absorb than week 8 results. By the close of Build, every architectural choice has been validated against real biotechnology data, not against a synthetic benchmark.

What the first 30 days actually look like on document processing for biotechnology is rarely communicated in vendor decks — so we describe it concretely here. Kickoff Monday: alignment on the labelled test set methodology, the integration scoping for ELN, the success metric definitions. By Wednesday, an initial 50-case labelled test set is in place, drafted by your operator team and reviewed by our delivery lead. By Friday, the retrieval index has its first batch of approved sources, indexed and queryable.

Week 2 is integration and prompt-strategy week. We connect to ELN, expand the labelled test set to 150+ cases, and ship the first prompt iteration against the harness. The Friday demo shows initial accuracy numbers on the test set — deliberately not impressive yet, but real. Week 3 is the action-layer week: draft generation, reviewer queue UI, audit log instrumentation. Friday demo shows the first end-to-end case flow.

Week 4 is the thin-slice production week. We deploy to a narrow audience (5-10% of routine cases), instrument the operator feedback loop, and run the first weekly performance review with your team. By end of day-30, the workflow is processing real biotechnology traffic with the calibration loop closing, and the next phase of Build is scoped from concrete evidence.